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INTRODUCTION
Cardiovascular disease (CAD) is a general
descr ip t ion  incorpora t ing  severa l
pathologies including coronary heart
disease, stroke and venous thrombosis.
CAD is the main cause of morbidity and
mortality in Western countries (Murray &
Lopez, 1997). Differences in the incidence
of hypertensive heart disease and coronary
heart disease, atherosclerosis and cardiac
remodeling after myocardial infarction (MI)
between males and females are well
established (Mendelsohn & Karas, 1999;
Stevensen, 2000). Estrogen improves well-
defined risk factors, such as lipid profiles;
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ABSTRACT
The incidence of cardiovascular disease (CAD) differs between men and women, in part because of differences in
risk factors and hormones. This sexual dimorphism means a lower incidence in atherosclerotic diseases in
premenopausal women, which subsequently rises in postmenopausal women to eventually equal that of men. These
observations point towards estrogen and progesterone playing a lifetime protective role against CAD in women. As
exogenous estrogen and estrogen plus progesterone preparations produce significant reductions in low-density
lipoprotein (LDL) cholesterol levels and significant increases in high-density lipoprotein (HDL) cholesterol, this
should in theory lower the risk of CAD. However, results from oral contraceptive (OC) use and combined estrogen
and progesterone hormone replacement therapy (HRT) have suggested that hormone replacement regimes do not
provide cardiovascular protection. In fact, depending on the preparation and the presence or absence of genetic risk
factors, an increased risk of cardiovascular diseases such as venous thrombosis, myocardial infarction (MI) and
stroke have been observed. Interestingly, in the majority of studies the increase in risk was highest in the first year,
after which an increase in risk was not observed, and in some studies a lower risk of CAD was evident after four or
five years of exogenous hormone administration. While the debate continues about the merits of HRT, and several
good reviews exist on the statistics of CAD in relation to exogenous hormones, we have decided to review the
literature to piece together the physiological actions of estrogen and progesterone preparations on the individual
mechanistic components leading to CAD; namely, the altered endothelium and the haemostatic balance between
coagulation and fibrinolysis. We present possible mechanisms for how HRT and OCs protect against MI in the
absence of cardiovascular risk factors but increase the incidence of MI in their presence. We also speculate on the
roles played by hormones on the short- and long-term risks of cardiovascular disease.
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estrogen, progestins, venous thrombosis, myocardial infarction.
it also has direct effects on the myocardium,
endothelium, and vascular smooth muscle
(VSM).  Es t rogens  enhance  f low of
choles te ro l  f rom the  d ie t  th rough
chylomicrons and chylomicron remnants
to the liver, through very low-density
l ipoprotein (VLDL) and low-densi ty
lipoprotein (LDL) to cells, and through
reverse cholesterol transport from cells via
high-density lipoprotein (HDL) to the liver
to be finally eliminated in the bile and
intestine (Knopp, 1997). Estrogen increases
levels of VLDL and subsequently the levels
of triglycerides, decreases LDL levels due
to the up-regulation of LDL receptors, and
increases HDL due to increased secretion
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of apoA-I and reduced removal of HDL due
to a reduction in hepatic lipase activity
(Knopp, 1997; Espeland et al., 1998; Zhu
et al., 1999; Mendelsohn & Karas, 1999;
Table I).
Estrogen is widely regarded as having
beneficial effects on the three layers of the
arterial wall; the intima (endothelium), the
media, and the adventitia. These beneficial
ef fec ts  inc lude  reduct ion  in  p lasma
fibrinogen, plasminogen activator inhibitor
(PAI-1) activity, reduced LDL oxidation in
plasma, enhanced glucose metabolism, and
enhanced insulin resistance (Knopp, 1997;
Espeland et al., 1998; Mendelsohn & Karas,
1999; Cushman et al., 1999; Sack et al.,
1994; Table I). In the arterial endothelium,
estrogen increases nitr ic oxide (NO)
synthase activity and NO production
(Hishikawa et al., 1995; Caulin-Glaser et
al., 1997; Table I). NO is beneficial to
arterial vasomotion in women who have
angina pectoris due to vasospasm (Guetta
and Cannon, 1996). In the intima and media
of the arterial wall, estrogen reduces
calcification and secretion of inflammatory
cytokines, such as fibroblast growth factor
(FGF), inter-cellular adhesion molecule
(ICAM-1), vascular cell adhesion molecule
(VCAM-1), endothelial- and platelet-
selectin (E- and P-selectin), nuclear factor
kappa B (NFκB) and consequently reduces
the atherosclerosis which is associated with
release of these cytokines in animal models
(Knopp, 1997; Guetta and Cannon, 1996;
Adams et al., 1990; Haarbo et al., 1991;
Table I).
Conflicting results have been reported on
the effects of progestins on atherosclerosis.
Several studies demonstrate no effect in
both primate and cholesterol-fed rabbit
models (Adams et al., 1990; Haarbo et al.,
1991). However, other studies have shown
that natural progesterone and synthetic
progestins oppose the beneficial effects of
estrogen (Hanke et al., 1996; Adams et al.,
1997). Progestins have been reported to
oppose the estrogen-induced increase in
plasma NO metabolites (Imthurn et al.,
1997) which indicates that progestins
inhibit NO production in endothelial cells
and  i s  fur ther  ev idence  of  the
proatherogenic effects of progestins in the
presence of estrogen. Progestins appear to
reduce the stimulatory effect of estrogens
on lipoprotein transport in the bloodstream.
For example, VLDL secretion is reduced;
remnant  removal  i s  impai red ,  LDL
receptors are down-regulated, increasing
LDL-cholesterol levels; and HDL levels
are reduced in response to increased hepatic
lipase activity. Progestins also increase
glucose, insulin and fibrinogen plasma
levels (Knopp, 1997).
The estrogen receptor (ER) is classically
a ligand-dependent nuclear transcription
factor. However, recent evidence indicates
that non-nuclear liganded ER can also
regulate the activity of intracellular second
messengers and membrane-associated
receptors and signaling complexes (Ho &
Liao, 2002). In the cardiovascular system,
these non-nuclear signaling pathways
mediate rapid vasodilatation (White et al.,
1995), inhibition of the response to vessel
injury (White et al., 1997; Sullivan et al.,
1995), reduction in myocardial injury after
infarc t ion  (Node  e t  a l . ,  1997) ,  and
at tenuat ion  of  card iac  hyper t rophy
(Douglas et al., 1998). The importance of
estrogen in the cardiovascular system has
been elucidated from ER knockout and
mutation studies. In a single case study, a
young man presented with homozygous
disruption of the ERα gene, which resulted
in the expression of a truncated receptor
lacking both DNA and hormone-binding
domains. This patient developed premature
CAD and impaired brachial endothelium-
dependent vasodilatation providing further
evidence for a developmental and protective
role for estrogen in the heart and protection
from CAD (Sudhir et al., 1997a; Sudhir et
al., 1997b). Studies in ovariectomized mice
show that 17ß-estradiol inhibits intimal and
media l  vascular  smooth  musc le
proliferat ion (Sull ivan  et  al . ,  1995),
implying a protective role for estrogen on
both endothelial cells (EC) and vascular
smooth muscle cells (VSMC). In ER knock-
out mice, 17ß-estradiol also inhibits medial
thickening and VSMC proliferation in
carotid injury studies (Iafrati et al., 1997).
This suggests that the vascular protection
produced by estrogen may be mediated in
an ERα-independent manner. Furthermore,
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when hearts from these mice are subjected
to ischemia-reperfusion they present a
greater degree of global ischemia and higher
incidence of arrhythmias (Zhai et al., 2000).
Studies which show that ovariectomized
ERαKO mice exposed to cerebral ischemia
have strokes which affect a greater area of
the brain also demonstrate that ERα
mediates the neuroprotective effects of
estrogen (Dubal et al., 2001). Evidence is
also mounting that ERβ also has a role to
play in the cardiovascular system. ERß
expression is induced in VSMC after
vascular injury (Linder et al., 1998), and
ERβKO mice are hypertensive and have
VSMC ion channel dysfunction (Zhu et al.,
2002).
OVARIAN HORMONES AND CARDIOVASCULAR
DISEASE
Venous disease
Although sexual dimorphism converts to a
lower incidence in arterial diseases in
premenopausa l  women,  exogenous
hormones  in  the  form of  OCs and
postmenopausal HRT have been associated
with increased risk of venous thrombosis,
MI and stroke. The presence of hormone
preparations appears to add to the increased
risk of venous thrombosis caused by genetic
factors such as personal or family history,
Factor V Leiden, deficiencies of protein C,
pro te in  S ,  o r  an t i th rombin  I I I  and
hyperhomocysteinemia. Emerging studies
show that in vitro fertilization treatment
and ovulation induction are also risk factors
for venous thrombosis (Bloemenkamp et
al., 2003). The risk for venous thrombosis
is highest during the first year of OC use.
Furthermore, OC users with inherited
clotting defects develop venous thrombosis,
not only more often, but also sooner, than
do those without inherited clotting defects
(Bloemenkamp et al., 2000). The nature of
the exogenous hormone regime is also a
risk factor  (WHO, 1995).  While the
concentrations of estrogen have been
declining since the first OC usage in the
late 1950s, from values as high as 100 ug
mestranol to 15 ug ethinyl estradiol, the
progestin dosage has remained relatively
constant. The World Heath Organization
(WHO) concluded that although current
users  of  es t rogen  and  proges te rone
combined contraceptives have a low
absolute risk of venous thromboembolism,
their risk is still three to six times greater
than that of nonusers, with the risk probably
being highest during the first year of use
(WHO, 1997). Although conflicting reports
exist, the increase in venous thrombosis
risk remains constant despite changes in
the nature and dosage of estrogen. The
progestin component, essential to suppress
ovulation, has changed only in composition
from first generation to third generation.
As with estrogenic compounds,  each
progestin has been associated with an
increased risk of CAD. This risk has been
demonstrated to be greater for the newer
th i rd-genera t ion  than  f rom second-
genera t ion  proges t ins  (Farmer  &
Lawrenson, 1998).
The picture for CAD is no brighter in
women tak ing  HRT prepara t ions .
Unopposed estrogen treatment,  while
delivering beneficial relief from post-
menopausal symptoms, also results in
endometr ia l  d i sorders  such  as
endometriosis and cancer (Smith et al.,
1975; Berger & Fowler, 1997). Estrogen
replacement therapy is still given to women
who do  not  have  a  u te rus ,  and
medroxyprogesterone acetate (MPA) is
added to the majority of current HRT
preparations to counteract the endometrial
abnormalities which arise from unopposed
estrogen administration. In a trial of oral
conjugated equine estrogen plus MPA, no
overall reduction in CAD events was
observed in postmenopausal women with
established coronary disease. However, the
treatment did lead to an increase in the rate
of thromboembolic events and gallbladder
disease (Hulley et al., 1998). As with OC,
the intriguing observation was made that
the risk of thrombotic events was higher in
the first year of use, and there was a
suggestion that the risk decreased to below
control (placebo) levels after four to five
years of treatment (reviewed in Rosendaal
et al., 2002). This emerging pattern for
exogenous hormone preparations indicates
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that there is a decreased risk of arterial
disease while at the same time an increased
the risk for venous thrombosis. Whether a
common mechanism of coagulation and
inflammation contributes to both responses
is unclear. Furthermore, there are two
separate phases in venous thrombosis: a
significant increase in risk in the short
term, with a plausible reduction in risk
associated with long-term use.
Arterial disease
Atherosclerosis is a progressive disease
which is characterized by the accumulation
of lipids and fibrous elements in the walls
of large arteries and constitutes the most
important factor in the growing incidence
of CAD. Several risk factors, such as
cigarette smoking, diabetes, hypertension
and elevated serum lipid concentration,
have been shown to increase the incidence
and accelerate the progression of the disease
(Multiple risk factor intervention trial,
1982; Castelli, 1996). Atherosclerosis is
responsible for MI and stroke, as well as
for their respective precursor disorders,
angina pectoris and transient ischemic
cerebral  at tacks (Born  et  al . ,  1991).
Atherosclerosis is a focal intimal disease
of arteries from the aorta down to vessels
of 3 mm external diameter. However, not
all arteries are equally susceptible; the
in te rna l  mammary  ar te ry  i s  mos t ly
unaffected while coronary arteries are at
high risk (Davies and Woolf, 1993). The
increased risk of MI and ischemic and
hemorrhagic stroke associated with oral
contraceptive usage appears elevated only
in women with hypertension or who smoke,
the risk being negligible in the absence of
these risk factors.
Clinical symptoms of atherosclerosis
depend on four mechanisms: 1) lipid
accumulation and connective tissue matrix
production can increase plaque volume so
that it encroaches on the lumen and impedes
blood flow. 2) A plaque can enter an
unstable phase and fissure which leads to
thrombus formation. The thrombus can
encroach  or  occ lude  the  lumen or ,
alternatively, embolize, impact and occlude
a smaller  distal  vessel .  3)  Although
atherosclerosis is a focal disease, it is
associated with a generalized abnormality
in vascular tone in affected vessels which
favors vasoconstriction, especially during
stress and exercise. 4) Medial atrophy and
destruction can lead to aneurysm formation
(Davies and Woolf, 1993).
Many hypothesis of atherogenesis have
been proposed. These tend not to be
mutually exclusive and differ more in the
emphasis given to particular events rather
than to opposing points of view. It is well
accepted that lipid accumulation in the
arterial wall, caused by hyperlipidemia, is
the initial step. Recently, advances in
cellular and molecular biology have focused
on the role of inflammation in atherogenesis
(Figure 1). In many animal models, signs
of  inf lammat ion  a re  observed
simultaneously with lipid accumulation. In
both experimental animals and humans,
blood leukocytes, mediators of the immune
response and inflammation, attach to the
endothelial cells that line the intima. The
normal endothelium does not support the
binding of white blood cells. However, soon
after the start of an atherogenic diet,
endothelial cells begin to express on their
surface adhesion molecules capable of
binding leukocytes (Huo & Ley, 2001).
Among these adhesion molecules, VCAM-
1 and ICAM-1 bind monocytes and T
lymphocytes found in early atheroma (Steps
1 & 2, figure 1) (Libby et al., 2002a, b).
Increased VCAM-1 expression is also
localized to sites prone to atherogenesis,
such as branch points in arteries where
endothelial cells are subject to disturbed
blood flow (Topper et al., 1996). Serum
levels of soluble P-selectin and ICAM-1
are also elevated in patients with peripheral
atherosclerotic disease (Huo and Ley,
2001). Abnormal laminar shear stress
reduces NO production which in turn
increases VCAM-1 expression (De Caterina
et  a l . ,  1995).  Progest ins  inhibi t  NO
production (Imthurn et al., 1997). It is
widely reported that estrogen replacement
therapy decreases VCAM-1 expression,
thereby providing a potentially-protective
mechanism to early atherogenic processes
(Nathan & Chaudhuri, 1997; Seljeflot et
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Figure 1. Hormonal effects on the atherogenic process. A. expression of inflammatory and adhesion molecules; initial lipid
infiltration and accumulation. B. Plaque growth and increased LDL deposition. C. Plaque rupture and thrombus formation.
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al., 2000; Table I). An increase in reactive
oxygen species (ROS) in the endothelium,
intima and adventitia also plays a major
role in the deposition of LDL. Risk factors,
such  as  hyperhomocys te inemia  and
smoking, increase the oxidation of LDL
(oxLDL) and thus deposition through
expression of scavenger receptors in the
arterial  wall  (Harrison  et al . ,  2003).
Increased shear stress may also induce
formation by VSMC of proteoglycans that
bind lipoprotein particles, facilitating their
oxidative modification and further inducing
an inflammatory response (Lee et al., 2001)
(Step 3, figure 1). Once the leukocytes
have adhered to the endothelium and an
inf lammatory  response  i s  in i t ia ted ,
monocytes penetrate the intima in response
to monocyte chemoattractant protein-1
(MCP-1) (Gu et al., 1998), (Step 4 & 5,
figure 1). Once in the arterial wall, the
monocytes differentiate into macrophages
in  response  to  macrophage  co lony-
stimulating factor (M-CSF) (Step 4 & 5,
figure 1) (Qiao et al., 1997). Estrogen
decreases the expression of MCP-1 and M-
CSF thereby decreasing monocyte adhesion
to endothelial cells and monocyte migration
into the subendothelial space (Nathan &
Chaudhuri, 1997). Monocyte adhesion and
migration produce a localized inflammatory
response in which tumor necrosis factor
beta (TNFß) and interferon gamma (INFγ)
are released by macrophages (Step 6, figure
1). During this stage, expression of C-
react ive protein (CRP),  a  marker of
inflammation, is also increased. Combined
estrogen and progesterone therapy increases
CRP expression and therefore may further
increase the damage induced by the
inflammatory response (van Baal et al.,
1999b, c; Skouby et al., 2002). These
macrophages  a l so  have  increased
expression of the scavenger receptor A and
CD36 which  in te rna l ize  modi f ied
lipoproteins (minimally modified and
oxLDL), accumulating cholesteryl esters
in the form of cytoplasmic droplets, leading
to foam cell formation which characterize
the fatty streak, a hallmark of the early
atherosclerotic lesion (Step 7 & 8, figure 1)
(Libby, 2002a, b). Estrogen also decreases
LDL oxidation, thereby preventing foam
cell formation and lesion progression
(Crook, 2001; Tedeschi-Reiner & Reiner,
2001; Table I).
Growth factors, inflammatory mediators
and proteolytic enzymes released by foam
cells induce smooth muscle cell replication,
which accumulate in the plaque and lay
down extracellular matrix, transforming the
fatty streaks into a complicated atheroma.
As the lesion grows, it narrows the arterial
lumen, interfering with blood-flow and
causing clinical symptoms, such as angina
pectoris or acute MI (Steps 9-11, figure 1).
This apparently smooth progression of
plaque growth is frequently marked by
bursts in growth of the atheroma (Yokoya
et al., 1999). There is evidence to suggest
that physical disruption of plaques may
trigger thrombosis and promote sudden
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expansion of the atheroma (Davies, 1996).
The most common mechanism of plaque
disruption is a fracture of the plaque’s
fibrous cap through the elaboration of
proteases, such as the matrix-degrading
neutral metalloproteinases. This cap serves
to separate the thrombogenic lipid-rich core
of the atheroma from the bloodstream,
which contains coagulation factors. Fissure
of the fibrous cap allows contact between
coagulation factors and tissue factor (TF),
the main pro-thrombotic element in the
lipid core, causing blood coagulation.
Subsequently, platelets become activated
by thrombin, generated by the coagulation
cascade and by contact with the intimal
compartment, causing thrombus formation.
If the thrombus occludes the artery, it can
cause an acute MI (Libby, 2002a, b).
HORMONES AND THE COAGULATION PATHWAY
The intrinsic coagulation pathway starts with
injury to the vessel wall, with exposure of
sub-endothelial collagen. The first step in
this pathway is the conversion of Factor XII
to Factor XIIa. The presence of OCs
increases the concentration of Factor XII
(Gordon et al., 1983). Factor XIIa promotes
the activation of Factor XI to Factor XIa,
which in turn activates Factor IX. Factor IX
has been shown to be increased in women
taking HRT (Lowe et al., 2001). HRT
preparations have also been associated with
a decrease in plasma levels of Factor VIII
(Acs et al., 2002). The combination of Factor
IXa and Factor VIII promote the activation
of Factor X. On the other side, the extrinsic
pathway is initiated by the exposure of Tissue
Factor (TF) to circulating Factor VII. TF has
been extensively reported to be regulated by
exogenous ovarian hormone treatments.
Holschermann et al. (1999) reported an
increase in  TF expression by blood
monocytes in the presence of OCs that may
favor intravascular clotting activation.
Furthermore, several HRT preparations have
been demonstrated to lower TF levels in the
endothelium, but at the same time increase
TF/Factor VIIa activity (Koh et al., 2001).
The circulating levels of Factor VII are also
altered in response to HRT. In short-term
studies (up to one year), cyclic regimes of
estrogen and progesterone demonstrate that
unopposed estrogen increases Factor VII
concentration, an effect which was reversed
upon addition of progesterone (Bladbjerg et
al., 2002; Lowe et al., 2001; Cushman et al.,
1999). Other reports have observed a
decrease in Factor VII levels after six weeks
of combined treatment HRT (Peverill et al.,
2001), while others have shown a differing
increase in Factor VII depending on the
generation of progestin used in OCs (Kluft
2000). The active complex of TF/Factor
VIIa is inhibited by tissue factor pathway
inhibitor (TFPI) (Badimon et al., 1999). This
protein is down-regulated by estrogen and
HRT and OC combinations (Bladbjerg et
al., 2002; Peverill et al., 2001; Luyer et al.,
2001; Harris et al., 1999), leading to the
presence of a hypercoagulable state.
Proteolytic cleavage result ing in the
formation of  Factor  VIIa  leads,  in
collaboration with TF, to the activation of
Factor X (Factor Xa). This conversion point
of the intrinsic and extrinsic pathways
promotes the conversion of the soluble blood
protein prothrombrin to thrombin. Factor
Va also plays a regulatory role in this process.
The presence of a mutation in factor V,
known as Factor V Leiden, greatly increases
the risk of venous thrombosis associated
with OCs 30-50 times (Bauer,  2002;
Vandenbroucke et al., 2001). Increases in
circulating levels of prothrombrin are
observed with unopposed estrogen and HRT
treatment (Vahkavaara et al., 2001; Peverill
et al., 2001, respectively). The net results of
these regulations have led to reports of
increased levels of thrombin in the presence
of estrogen and HRT (Norris et al., 2002;
Vahkavaara et al., 2001; Peverill et al.,
2001). The amino acid fragment (F1+2),
which is generated during prothrombin
activat ion and thus provides a good
indication of thrombin levels, was shown to
be increased in the presence of HRT, and
these levels were higher in women who
subsequently developed recurrent venous
thrombosis (Hoibraaten et al., 2001; Cano
& Van Baal, 2001). Thrombin has several
roles: firstly to promote the formation of
fibrin from fibrinogen; and secondly, to form
a complex with thrombomodulin. This
MEDINA ET AL. Biol Res 36, 2003, 325-341
332
complex can also down-regulate  the
circulating levels of thrombin (dashed line
with negative sign in Figure 2). In contrast
to the above mentioned hormonal regulation
of the coagulation cascades, combined
estrogen and progestin treatments display
anticoagulant activity by lowering the
circulating levels of the fibrin precursor
fibrinogen (Acs et al., 2002; Cushman et al.,
1999; van Baal et al., 1999b; Norris et al.,
2002; Table I). HRT has also been reported
to increase fibrin turnover (Sidelmann et al.,
2003). Finally, in clot formation Factor
XIIIa, a transglutaminase, crosslinks the
fibrin monomers. The degradation of the
clot in the processes leading to fibrinolysis
is regulated by sex steroid hormones (Table
I). As mentioned above, thrombin forms a
complex with thombomodulin which in turn
act ivates  Protein C.  Reports  are
contradictory on the effect of hormones on
the levels of activated protein C (APC).
Some reports demonstrate higher levels in
the presence of HRT (Lowe et al., 2001),
while others show a reduction (Hoibraaten
et al., 2000; Lowe et al., 2001). APC
inactivates Factor V, Factor VIIIa (by
proteolyt ic  c leavage)  and PAI-1.
Interestingly, the risk factor, Factor V
Leiden, has diminished sensitivity to APC
favoring a coagulation state. In accordance
with this effect, elevated Factor VIII levels
are associated with an increased risk of deep
vein thrombosis (Koster et al.,  1995;
Kamphuisen et  al . ,  2001).  A further
ant icoagulant  act ion of  hormones is
demonstrated by both unopposed estrogen
(Vahkavaara et al., 2001) and HRT-reducing
circulating levels of PAI-1 (Lowe et al.,
2001; Koh, 2002; Cushman et al., 1999;
Table  I ) .  PAI-1 inact ivates  t issue
plasminogen act ivator  ( t -PA) and
plasminogen activator type-urokinase (u-
PA). The conversion of plasminogen to
plasmin, which participates in fibrinolysis,
is regulated by both u-PA and by t-PA.
Interestingly, at this stage, hormones create
a balance between promoting and reducing
plasmin levels. Levels of plasminogen are
increased by both estrogen (Luyer et al.,
2001) and HRT (Acs et al., 2002), while t-
PA levels have been reported to be reduced
by estrogen (Vahkavaara et al., 2001) and
HRT (Lowe et al., 2001; Koh, 2002).
However, Hoetzer et al. (2003) reported that
estrogen could increase t-PA levels 30%
compared to controls, while the addition of
progesterone, in HRT, reversed this effect.
As it is clear that hormones have a strong
procoagulative role (on the generation of
thrombin) and that there exists a fine
hormonal balance in the promotion or
inhibition of fibrinolysis, depending on the
regime and dosage, hormones may increase
or decrease the coagulative potential and
thus impose either positive or negative
effects on cardiovascular disease.
COAGULATION AND CAD
Coagulation and venous thrombosis
Estrogen and combined estrogen and
progestin exogenous preparations alter the
coagulable state (reviewed in Figure 2). An
increase in the concentration of blood
procoagulants may initiate clotting and lead
to thrombosis formation increasing the risk
of venous thrombosis. This clot may
disengage from the vessel wall and flow,
via the right side of the heart, to the
pulmonary arteries causing pulmonary
embol i sm.  The  increase  in  venous
thrombosis risk is concentrated in the first
year of treatment. As demonstrated in
Figure 2 and the accompanying text,
exogenous hormones maintain a delicate
balance between pro– and anti-coagulative
states. To date there is insufficient clinical
data relating to the levels of coagulation
cascade  in te rmedia tes  to  draw f i rm
conclusions, but initial reports suggest there
may be an increase in fibrinolytic activity
with duration of hormonal usage (Salobir
et al., 2002).
Coagulation and atherosclerosis
Clotting at the site of the lesion may involve
both the intrinsic and extrinsic coagulation
pathways (Khrenov et al., 2002a). The
extrinsic, TF-dependent, pathway plays a
major  ro le  in  de te rmining  the
thrombogenicity of atherosclerotic lesions
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and subsequent  genera t ion  of  acute
coronary syndromes (Toschi et al., 1997).
In the normal vessel, TF is not expressed
on endothelial cells or monocytes which
are exposed to the circulating blood. TF is
restricted to the adventitia and VSMC of
the media (Wilcox et al., 1989). However,
in atherosclerotic lesions, high levels of TF
mRNA and protein can be found in all three
cell types which make up the vessel wall
(Moreno et al., 1996). Furthermore, TF
expression levels have a high degree of
correlat ion with plaque severi ty and
vulnerability (Ardissino et al., 1997).
Al though the  ext r ins ic  pa thway is
responsible for the initiation of thrombus
formation, there is mounting evidence that
it is solely responsible for the occlusive
thrombus formation (Sramek et al., 2001;
Bilora et al., 2001; Rosendaal et al., 1990;
Triemstra et al., 1995). This implies that
the intrinsic pathway, which activates factor
X 50-fold more efficiently and amplifies
the coagulation triggered by the TF-
dependent pathway (Mann, 1999), also
contributes to thrombogenicity of the
atherosclerotic lesion.
Recent evidence indicates that the LDL/
HDL ratio may also affect coagulation.
Increased LDL concentrations have a
procoagulant effect (Moyer et al., 1998)
whereas HDL acts as an anticoagulant
(Griffin et al., 1999). The mechanism
responsible for these effects seems to be
lipoproteins providing a phospholipid
surface where the assembly of enzymatic
complexes of the coagulation cascade can
take place. Specifically, VLDL and oxLDL
can support prothrombinase activity and
LDL supports extrinsic and intrinsic Xase
activity (Khrenov et al., 2002b). While the
abi l i ty  of  l ipopro te ins  to  suppor t
coagulation complex assembly is far less
than that observed in platelets, enriched
LDL and oxLDL present in the lipid-rich
core may play an important role in Xase
Figure 2. Hormonal effects on the coagulation cascade.
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and prothombinase complex assembly,
adding to the thrombogenicity of the lesion.
As mentioned above, estrogen decreases
LDL and increases HDL levels, while
progestins have the opposite effect.
The accumulation of oxLDL within the
plaque induces pathological changes in all
vesse l  wal l  ce l l s ,  increas ing
thrombogenesis (Khrenov et al., 2002a).
Oxidized LDL induces TF expression in
endothel ia l  ce l l s  (Fei  et  a l . ,  1993) ,
macrophages (Brand et al., 1994) and
VSMC (Penn et al., 2000). Accumulated
oxLDL may also enhance the ability of
atherosclerotic lesion cells to form the
phospholipid surface required for the
assembly  and ac t iv i ty  of  enzymat ic
complexes  of  the  intr insic  pathway.
Exposure of human macrophages and
VSMC to oxLDL increases their ability to
support Xase and prothrombinase complex
activi ty,  greatly increasing thrombin
formation (Ananyeva et al., 2002). This
increase in intrinsic pathway procoagulant
activity is related to increased expression
of factor VIII binding sites and more
efficient assembly of Xase complex due to
increased exposure of phosphatidylserine
(PS) on oxLDL-treated cells (Wintergerst
et al., 2000). This data indicates that the
intrinsic pathway may play an important
role in upregulating the thrombogenicity
of  a therosc lero t ic  les ions  fo l lowing
endothelial layer removal and subsequent
exposure of VSMC and macrophages to
blood flow.
Although apoptotic cells are absent from
normal arteries,  they are common in
advanced plaques and include VSMC,
macrophages  and  T lymphocytes
(Bjorkerud & Bjorkerud, 1996). Apoptosis
can be induced by a variety of agents;
however, apoptosis is probably mediated
by oxLDL within the plaque (Okura et al.,
2000).  One of  the characterist ics  of
apoptotic cells is the translocation of PS
from the inner to the outer surface of the
plasma membrane by a loss of membrane
phospholipid asymmetry. The increased
expression and accessibility of PS on the
outer surface of the plasma membrane
increases the thrombogenic potential of
these cells by providing a platform for the
assembly of complexes of both intrinsic
and extrinsic coagulation pathways (Gilbert
& Arena, 1996). Another thrombogenic
effect of apoptotic cells present in the
plaque is the shedding of PS- and TF-rich
microparticles (Mallat et al., 1999; Bombeli
et al., 1997).
Thrombogenic i ty  i s  re la ted  to  up-
regulation of both intrinsic and extrinsic
pathways. However, down-regulation of
anticoagulant and fibrinolytic activity may
also  cont r ibu te  to  a thero thrombosis
(Khrenov et al., 2002a). Oral contraceptives
have been demonstrated to lower the
sensitivity of factors involved in thrombin
generation to APC, thus promoting a more
coagulative state (reviewed in Cano & Van
Baal, 2001). There is further evidence which
shows that  thrombomodul in  and the
endothe l ia l  ce l l  p ro te in  C receptor
express ion  a re  down-regula ted  in
atherosclerotic plaques (Laszik et al., 1994).
Since HDL increases protein C activity,
this down-regulation may be associated
with decreased HDL levels observed in
atherosclerosis (Griffin et al., 1999).
THE BENEFITS AND THE RISKS OF EXOGENOUS
HORMONES IN ARTERIAL DISEASE
The paradox of why exogenous hormones
increase  the  shor t - te rm r i sk  of
cardiovascular disease yet may lower long-
term evident risk may be related to the
nature of the genesis of venous thrombosis
and  MI .  MI  i s  a  consequence  of
atherosclerosis, while venous thrombosis
is a disease of the veins which arises from
hypercoagula t ion and venous  s tas is .
Arteries are larger than veins and have
greater flexibility brought about presence
of an elastic layer. Movement of the wall of
the endothelium is maintained by a delicate
balance of dilating factors, such as NO and
bradykin in ,  in  combina t ion  wi th
constricting factors, such as angiotensin-
II, thromboxane, and endothelin among
others (reviewed in Cano & Van Baal,
2001). These may be contributing factors
as to why arterial disease and myocardial
infarction have a lower incidence than
venous thrombosis. Another important
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Figure 3. Role of hormone replacement therapy (HRT) in atherogenesis in women with and without cardiovascular risk factors.
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factor is the process of atherogenesis which
occurs only in the arteries. As previously
mentioned, exogenous hormones only
increase the risk of MI in the presence of
cardiovascular risk factors. As depicted in
Figure 3 (Scenario A) using HRT as an
example in women with no risk factors the
increase  in  b lood  procoagulants
(hypercoagulative state) will not lead to
thrombosis formation, due to the size and
movement of the artery, and thus the
beneficial effects of estrogen in preventing
the formation of an atherosclerotic plaque
may provide long-term protection against
MI and stroke. These beneficial effects of
exogenous hormones include: 1) lowering
LDL and raising HDL (Table I); 2) reducing
intimal damage on vessel walls (Table I);
3) lowering the expression of adhesion
molecules such as E-selectin and sICAM-1
(Van Baal et al., 1999a; Table I); 4)
lowering MCP-1 (Stork et al., 2002) and
(5) increasing anticoagulant APC activity.
However ,  when women combine
exogenous  hormones  wi th  prev ious
cardiovascular risk factors, an increase in
risk of MI is observed (Figure 3, Scenario
B). In this case, a risk factor such as
hypertension facilitates incorporation of
LDL into the arterial wall (Medina et al.,
1997), the first step in the formation of an
atherosclerotic plaque. This step is further
confounded by smoking, which leads to the
oxidation of LDL and thus enhanced
deposition. Once an atherosclerotic plaque
is formed (or is already present), the
lowering by estrogens and/or HRT of
soluble ICAM-1 and E-selectin and the
increasing levels of CRP and matrix
meta l lopro te inase-9  (MMP-9)  wi l l
destabilize the plaque (Cano & Van Baal,
2001; Stork et al., 2002; Piercy et al., 2002;
Zanger et al., 2000). When rupture of the
atherosclerotic plaque occurs, a process
which is also promoted by hypertension,
the coagulation cascade is initiated. In this
instant, the increased presence of TF, and
other factors, that exist in the presence of
exogenous  hormones  wi l l  p romote
coagulation and increase the clotting
potential, leading to more rapid and greater
clot formation and thus thrombosis and MI
(Figure 3). If thromboembolism, occurs a
high change of stroke will ensue. In support
of a hypercoagulable state being a risk
fac tor  on ly  in  the  presence  of  an
atherosclerotic plague, which is deposited
more frequently in the presence of the
above-mentioned risk factors, markers of
coagulation and fibrinolysis (such as t-PA,
PAI-1 fibrinogen, and D-dimer) are not
associated with increased risk of myocardial
infarc t ion ,  bu t  a re  assoc ia ted  wi th
atherosclerosis (Haverkate, 2002).
THE FUTURE OF EXOGENOUS HORMONES
The small increase in CAD in women using
OCs does not outweigh the benefits from
avoiding the trauma and complications
ar i s ing  f rom unwanted  pregnancies ,
especially in non-smokers with no prior
history or cardiovascular risk factors. Along
wi th  benef ic ia l  e f fec ts  on  mood,
osteoporosis and hot flushes, the HRT
preparations were to be a simple and safe
prophylactic for heart disease. This idea is
based on apparently foolproof logic:
premenopausal women have lower CAD,
take away the hormones at menopause and
the protection is lost, add back the hormones
and we get back the protection. What may
have appeared to be simple on paper has
proved to be a nightmare in the clinic.
Women are now facing the scenario that
not only are their HRT preparations not
delivering a protective effect, but that these
preparations may actually be putting them
at higher risk for CAD (certainly in the
short term).
Unfortunately, there are a number of
variables queuing up for consideration.
First, we have no evidence that if women
never went through menopause, that they
would  main ta in  the  card iovascular
protection as they grow older, since changes
in the coagulation system are known to
occur naturally with the aging process.
Second, although women develop CAD
about ten years later than men, they are
likely to fare worse after a heart attack
(Giardina, 2000). Third, the hormone
regimes given as HRT can never exactly
mimic  the  c i rcu la t ing  ba lance  and
concentrations present in premenopausal
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women. Neither will exogenous hormones
emulate the specificity of in vivo action
derived from the local expression of
hormones.
Although an in vivo  premenopausal
situation is never truly possible, the future
of HRT is not dead. The beneficial effects
of exogenous hormones are required by a
subset of women, and as life expectancy
increases with every generat ion,  the
postmenopausal phase will account for an
ever-increasing portion of a woman’s life.
The negative results from the Women’s
Health Init iat ive study (Wassertheil-
Smoller et al., 2003) may reflect the
combination of r isk factors,  such as
smoking, with hormonal preparations. In
the Women’s Health Initiative trial, 50% of
the women on HRT had smoked before or
continued to smoke during the study (Mueck
& Seeger, 2003). Estrogen turnover is
increased in women who smoke, reducing
the beneficial estrogenic actions (Mueck &
Seeger, 2003).
Through the vast array of data regarding
OCs, HRT and cardiovascular disease, a
beneficial effect or at the very least an
insurance of no increased CAD risk, does
appear to be present under tightly-defined
parameters. It is evident from these clinical
studies that the choice of exogenous
hormone, combined with personal history
and the presence of cardiovascular risk
factors need to be taken into consideration
before prescription. The feasibility of
screening for CAD risk factors may have to
be considered. Although the results are not
fully clear on the effects of HRT on CAD in
healthy, risk-factor-free women, the data
does suggest that HRT should not be
prescribed, at present, for the prevention of
cardiovascular  disease.  In  regard to
preparation and dosage, Rosendaal et al.
(2002) recommend that contraceptives with
30 ug ethinyl estradiol should be the first
choice and that third-generation progestins
should be avoided due to their association
with increased venous thrombosis.
The information accumulated to date has
mainly concentrated on estrogens as a major
risk factor, but increasing evidence supports a
role for progestins in pathogenesis. The
objectives now facing the scientist and the
clinician is to better understand the workings, at
the physiological and molecular level, of
estrogen and progesterone and to determine
where and when hormones are required and
apply them accordingly. Hopefully, the foolproof
plan was merely naive in its execution, while the
logic is still firmly in place.
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